Zacks Research Upgrades Aytu BioPharma (NASDAQ:AYTU) to Hold

Aytu BioPharma (NASDAQ:AYTU) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

A number of other equities research analysts have also issued reports on AYTU. Ascendiant Capital Markets lifted their target price on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Aytu BioPharma currently has a consensus rating of “Hold” and an average price target of $10.75.

Aytu BioPharma Trading Up 3.5%

NASDAQ:AYTU opened at $2.38 on Thursday. The stock has a market cap of $25.54 million, a PE ratio of -0.52 and a beta of 0.25. Aytu BioPharma has a fifty-two week low of $1.65 and a fifty-two week high of $3.07. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.12 and a quick ratio of 1.00. The stock’s 50-day moving average is $2.21 and its two-hundred day moving average is $2.37.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The company had revenue of $12.41 million during the quarter, compared to analysts’ expectations of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. As a group, equities research analysts forecast that Aytu BioPharma will post -0.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aytu BioPharma

Large investors have recently bought and sold shares of the business. Rothschild Wealth LLC acquired a new position in Aytu BioPharma during the fourth quarter worth $52,000. BlackRock Inc. bought a new stake in shares of Aytu BioPharma during the 2nd quarter worth about $49,000. XTX Topco Ltd acquired a new position in shares of Aytu BioPharma during the 4th quarter valued at about $67,000. DRW Securities LLC acquired a new position in shares of Aytu BioPharma during the 4th quarter valued at about $76,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the 3rd quarter valued at approximately $58,000. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.